McDermott Shares Insight on Immunotherapy in RCC – OncLive
OncLive |
McDermott Shares Insight on Immunotherapy in RCC
OncLive Immunotherapy has made an incredible impact on the treatment of patients with metastatic renal cell carcinoma (RCC), and is now beginning to make waves in other settings of the disease. However, though drugs such as nivolumab (Opdivo) have proven their … |
